BLAINJECTIONINJECTABLE
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIVESTYM (filgrastim-aafi) by Pfizer is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIVESTYM (filgrastim-aafi) is a biosimilar granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production in the bone marrow by binding to cell surface receptors and promoting proliferation and differentiation. It is used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy and to mobilize hematopoietic progenitor cells for collection and subsequent autologous transplantation. The drug works by enhancing neutrophil production and function without significant effects on other hematopoietic cell lines.
Peak
Competitive pressure of 30% suggests a mature market with moderate biosimilar competition; brand teams focus on oncology relationships and cost-of-care messaging rather than growth expansion.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIVESTYM offers exposure to Pfizer's established oncology infrastructure and managed care negotiations but carries limited career upside from new indication growth or launch momentum. Success depends on cost-of-care optimization, payer relationship management, and defending market share in a biosimilar-competitive landscape rather than driving primary demand.
Worked on NIVESTYM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.